SutroVax has received an award from CARB-X for up to $15 million in non-dilutive funding to develop a universal vaccine to prevent infections caused by Group A Strep bacteria...
A little more than a year after it raised $64 million to develop a next-gen pneumococcal conjugate vaccine, SutroVax is back with another raise. And this time, it's tapping an industry veteran to help steer the ship.